

# PreveCeutical Medical Inc.

08:50 06 Jul 2020

## PreveCeutical says cannabinoid Sol-gel formulations showed physical and chemical stability in study

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) announced Monday successful results from its cannabinoid Sol-gel product development program.

The Vancouver-based company said the results came from a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain (NTB) delivery.

PreveCeutical said it looked at the physical and chemical stability of formulations' components, which underwent three months of cold storage (2-8°C) as well as room temperature storage.

### READ: PreveCeutical executes pact for developing CBD Sol-Gel nasal spray formulation as a potential coronavirus treatment

As a result, "there was minimal indication of physical or chemical instability of the cannabinoid formulation over the study period," the company said in a statement.

Quality evaluation testing of cannabis extracts was conducted using high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS) profiles to generate chemical fingerprints that were later qualified, validated and verified using analytical grade cannabinoid standards, it added.

Based on the before and after HPLC testing, the company said the study found that the cannabinoid content within the formulation generally remained within the study's acceptance criteria.

PreveCeutical said it will conduct a further stability study program as and when required by the regulatory authorities, and in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

With the use of an applicator, the sustained-released Sol-gel formulations allow for the direct and prolonged delivery of cannabinoids to a patient's central nervous system.

PreveCeutical and its Australian partner are now developing a Sol-gel CBD formula that could fight off the ability of SARS-CoV-2, the virus that causes the coronavirus (COVID-19) disease, to infect nasal tissue.

"We are very pleased with these results. With the increasing evidence of the clinical benefit of cannabinoids, our cannabinoid sol-gel solution aims to meet our study target," said CEO Stephen Van Deventer. "We plan to protect this IP and will be looking to work with a suitable partner and progressing through preclinical to clinical study development."

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

**Price:** 0.04

**Market Cap:** \$19.68 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** PREV

**Listing:** CSE

**52 week High Low**  
0.1 0.01

**Sector:** Medical technology & services

**Website:** [preveceutical.com](http://preveceutical.com)

#### Company Synopsis:

*PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).